阿昔洛韦治疗慢性乙型肝炎的初步研究。

Preliminary studies of acyclovir in chronic hepatitis B.

作者信息

Smith C I, Scullard G H, Gregory P B, Robinson W S, Merigan T C

出版信息

Am J Med. 1982 Jul 20;73(1A):267-70. doi: 10.1016/0002-9343(82)90103-6.

Abstract

Three patients with HBsAg-positive and DNA-polymerase-positive chronic hepatitis were treated with increasing dosages of intravenous acyclovir. A fall in DNA polymerase activity was seen with all courses of acyclovir but no dose-response relationship was evident. In only one patient did DNA polymerase fall to zero where it has remained for five months. Two out of 10 courses were associated with significant side effects with the highest dosages of acyclovir but these promptly resolved when the agent was stopped. Acyclovir's apparently partial and transient action suggests that it will not have a role in the treatment of chronic hepatitis B virus infection.

摘要

对3例乙肝表面抗原（HBsAg）阳性且DNA聚合酶阳性的慢性肝炎患者使用剂量递增的静脉注射阿昔洛韦进行治疗。在所有阿昔洛韦疗程中均可见DNA聚合酶活性下降，但未发现明显的剂量反应关系。仅1例患者的DNA聚合酶降至零并持续了5个月。10个疗程中有2个疗程在使用最高剂量阿昔洛韦时出现了明显的副作用，但停药后这些副作用迅速消失。阿昔洛韦明显的部分和短暂作用表明它在慢性乙型肝炎病毒感染的治疗中不会发挥作用。